Skip to main content
Caplight Logo









Vesicle Therapeutics

Vesicle Therapeutics

Private
Niwot, ColoradoHealthcare & Life Scienceshttps://vesicletherapeutics.com/

Last Round

Grant

May 21, 2026

Total Funding Raised

$2.57M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Vesicle Therapeutics is a biotechnology company that develops programmable extracellular vesicles, known as gectosomes, to deliver macromolecular therapeutics to intracellular targets.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

extracellular vesiclesdrug delivery platformgectosomesantisense oligonucleotidesTMOtargeted drug deliverybiotech startupgenome editingtherapeutic proteinsnucleic acid deliverydrug delivery techbiotech licensingpreclinical biotechdrug discoveryprecision medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Vesicle Therapeutics Comparables

Compare Vesicle Therapeutics with similar companies based on industry and business-model similarity.

Vesicle Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Eascra Biotech
87%
SHIFTBIO
82%
Carus Bio
82%

Vesicle Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 21, 2026
GrantSep 16, 2025
GrantOct 28, 2024
GrantMay 19, 2022
GrantMay 1, 2022
Seed
Apr 5, 2022

Vesicle Therapeutics Investors

Notable investors and investment history

Vesicle Therapeutics investors
InvestorRounds
Venture Partners at CU BoulderGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 21, 2026

    $250K grant round completed.

  • Sep 16, 2025

    $400K grant round completed.

Vesicle Therapeutics Filings

Explore SEC and related filing metadata, where available.

Vesicle Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Vesicle Therapeutics's valuation, stock price, and market status.

Is Vesicle Therapeutics a public or private company?

Vesicle Therapeutics is a private company.

What is the current stock price of Vesicle Therapeutics?

Vesicle Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Vesicle Therapeutics worth (valuation)?

Valuation information for Vesicle Therapeutics is not publicly available.

Can I buy Vesicle Therapeutics stock?

Vesicle Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Vesicle Therapeutics's last funding round?

Vesicle Therapeutics's most recent funding round was Grant on May 21, 2026.

Who are the main investors in Vesicle Therapeutics?

Key investors in Vesicle Therapeutics include Venture Partners at CU Boulder.

Will Vesicle Therapeutics IPO soon?

No public IPO plans have been announced for Vesicle Therapeutics.

How can I track Vesicle Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Vesicle Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNiwot, Colorado
Year Founded2020
Last FundingMay 21, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?